Amgen raised its 2026 revenue and non-GAAP EPS guidance after a strong first quarter, driven by 24% growth from six key products. The company expanded its MariTide Phase III program to include ...

Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation Technology THOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: ...

Amgen Inc (AMGN) reports a robust 4% growth in product sales, driven by key growth drivers, while navigating patent expirations and increased competition.

Bio-Rad Laboratories lowered its 2026 revenue growth outlook to between -3% and +0.5% due to Middle East disruptions, while Amgen raised its full-year revenue and EPS guidance on strong product ...

In the news release, AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS, issued 30-Apr-2026 by Amgen over PR Newswire, we are advised by the company that changes have been made. The complete, ...